Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137812 · ClinicalTrials.gov registry record · Phase 3
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
- 20
- Study locations
NCT01137812: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development.
NCT01137812 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Janssen Research & Development. The registered enrollment target is 756 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01137812, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
Primary Outcome
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Canagliflozin 300 mg
- DRUG Sitagliptin 100 mg
- DRUG Sulphonylurea
Study Locations (20)
California
- - Escondido
- - Fresno
- - Greenbrae
- - La Mesa
- - Laguna Hills
- - Lancaster
- - Long Beach
- - Los Angeles
- - Norwalk
- - Pismo Beach
- - Roseville
- - Spring Valley
- - Walnut Creek
- - Watsonville
Arizona
- - Goodyear
- - Mesa
Colorado
- - Denver
- - Northglenn
Alabama
- - Mobile
Connecticut
- - Milford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
What the finished NCT01137812 record still lists
NCT01137812 is an interventional study that assigns participants to a tested intervention. The registered 756 participants enrollment target is mid-sized for trials with a published cap, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Metformin is the first listed.
NCT01137812 names 20 study sites across 5 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT01137812 about?
NCT01137812 is a clinical study titled "The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)". The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
What is the current status of trial NCT01137812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2010-07. Estimated completion is 2012-03.
What conditions does trial NCT01137812 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01137812?
The interventions under investigation include: Metformin (DRUG), Canagliflozin 300 mg (DRUG), Sitagliptin 100 mg (DRUG), Sulphonylurea (DRUG).
Who is sponsoring clinical trial NCT01137812?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01137812 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01137812's enrollment target sits among peer trials
756 49th of 348 higher than 300 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia